Angiotensin Therapeutics, Inc.
Biotechnology company developing engineered recombinant ACE2 protein variants designed to degrade excess angiotensin II and to act as decoy receptors for SARS-CoV-2. Their programs focus on shortened ACE2 constructs and fusion-tag strategies to extend plasma half-life and improve delivery to the kidney. Work includes in vitro antiviral protection studies, planned in vivo efficacy testing, and preparation to progress molecules toward clinical development; some programs are supported by NIH grants and licensed from an academic lab.
Industries
N/A
Nr. of Employees
small (1-50)
Products
ACE2 variants with prolonged half-life
Engineered soluble ACE2 protein variants with shortened sequence and fusion tags to increase kidney delivery and extend systemic duration of action for therapeutic use.
Soluble ACE2 protein candidate for viral interception
Soluble ACE2 construct developed as a decoy receptor to block SARS-CoV-2 spike binding; supported by NIH grant funding and demonstrated protective effect in human cell assays.
ACE2 variants with prolonged half-life
Engineered soluble ACE2 protein variants with shortened sequence and fusion tags to increase kidney delivery and extend systemic duration of action for therapeutic use.
Soluble ACE2 protein candidate for viral interception
Soluble ACE2 construct developed as a decoy receptor to block SARS-CoV-2 spike binding; supported by NIH grant funding and demonstrated protective effect in human cell assays.
Expertise Areas
- Recombinant protein engineering
- Renin–angiotensin system biology
- Renal-targeted therapeutics
- Preclinical antiviral and virology research
Key Technologies
- Recombinant protein engineering
- Fusion-tag half-life extension (albumin-binding domains)
- Kidney-targeting delivery strategies
- In vitro cell-based viral neutralization assays
News & Updates
Engineered ACE2 protein constructs were licensed from an academic laboratory to the company for development.
A soluble ACE2 protein program targeting SARS-CoV-2 received NIH grant support for preclinical development.
Engineered ACE2 protein constructs were licensed from an academic laboratory to the company for development.
A soluble ACE2 protein program targeting SARS-CoV-2 received NIH grant support for preclinical development.